Sequential or combination therapy for multiple myeloma

Expert Review of Hematology

Volumn 5, Issue 5, 2012, Pages 533-545

  Nooka, Ajay ^a   Lonial, Sagar ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bortezomib; combination therapy; cytotoxic therapies; lenalidomide; myeloma; novel agents; sequential therapy; thalidomide

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DELANZOMIB; DEXAMETHASONE; ELOTUZUMAB; IMMUNOMODULATING AGENT; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; OPROZOMIB; PANOBINOSTAT; PREDNISONE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; TANESPIMYCIN; THALIDOMIDE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; DRUG EFFICACY; FLOW CYTOMETRY; HEALTH CARE QUALITY; HUMAN; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS;

EID: 84869177971     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.49     Document Type: Review

References (110)

1. Anderson KC. New insights into therapeutic targets in myeloma. Hematology Am. Soc. Hematol. Educ. Program 2011, 184-190 (2011).
2. Patel AM, Ho VQ, Shain KH et al. Sequence of therapy in multiple myeloma: does it matter? Retrospective evaluation of patients with multiple myeloma who have received bortezomib followed by lenalidomide or vice versa. ASH Annual Meeting Abstracts 118(21), 3979 (2011).
3. Nooka AK, Kaufman JL, Behera M et al. The improved efficacy of bortezomib containing induction regimens (BCIR) versus non-bortezomib containing induction regimens (NBCIR) in transplant-eligible patients with multiple myeloma (MM): meta-analysis of Phase III randomized controlled trials (RCTs). ASH Annual Meeting Abstracts 118(21), 3994 (2011).
4. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1), 3-9 (2009).
5. Paiva B, Vidriales MB, Cerveró J et al.; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112(10), 4017-4023 (2008).
6. Rawstron AC, Orfao A, Beksac M et al.; European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93(3), 431-438 (2008).
7. Davies FE, Forsyth PD, Rawstron AC et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br. J. Haematol. 112(3), 814-819 (2001).
8. Ladetto M, Pagliano G, Ferrero S et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J. Clin. Oncol. 28(12), 2077-2084 (2010).
9. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Antimyeloma activity of heat shock protein 90 inhibition. Blood 107(3), 1092-1100 (2006).
10. Richardson PG, Chanan-Khan AA, Lonial S et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a Phase 1/2 study. Br. J. Haematol. 153(6), 729-740 (2011).
11. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood 109(11), 4839-4845 (2007).
12. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 13(6), 1625-1629 (2007).
13. Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem. Biol. 14(11), 1204-1206 (2007).
14. Peng C, Li D, Li S. Heat shock protein 90: A potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 6(18), 2227-2231 (2007).
15. Catley L, Weisberg E, Kiziltepe T et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108(10), 3441-3449 (2006).
16. Hideshima T, Bradner JE, Wong J et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. U.S.A. 102(24), 8567-8572 (2005).
17. Kikuchi J, Wada T, Shimizu R et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 116(3), 406-417 (2010).
18. David E, Kaufman JL, Flowers CR et al. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood 116(24), 5285-5288 (2010).
19. Lonial S, Boise LH. Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. Autophagy 7(4), 448-449 (2011).
20. Santo L, Hideshima T, Kung AL et al. Selective HDAC6 inhibition via ACY-1215, either alone or in combination with bortezomib, restores osteoblast function and suppresses osteoclast differentiation in multiple myeloma. ASH Annual Meeting Abstracts 118(21), 2908 (2011).
21. Badros A, Burger AM, Philip S et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 15(16), 5250-5257 (2009).
22. Weber DM, Jagannath S, Mazumder A et al in combination with bortezomib in patients with advanced multiple myeloma. ASH Annual Meeting Abstracts 110(11), 1172 (2007).
23. Harrison S, Quach H, Link E et al. High rate of durable responses in a phase I/II trial of the histone deacetylase inhibitor romidepsin combined with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 96(Suppl 1), 233 (2011).
24. Siegel DS, Dimopoulos MA, Yoon S-S et al. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global Phase 2b trial. ASH Annual Meeting Abstracts 118(21), 480 (2011).
25. Dimopoulos MA, Jagannath S, Yoon S-S et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized Phase 3 trial. ASH Annual Meeting Abstracts 118(21), 811 (2011).
26. Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003).
27. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
28. Orlowski RZ, Nagler A, Sonneveld P et al. Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25(25), 3892-3901 (2007).
29. Garderet L, Iacobelli S, Moreau P et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The MMVAR/IFM 2005-04 randomized Phase III trial from the chronic leukemia working party of the European group for blood and marrow transplantation. J. Clin. Oncol. 30(20), 2475-2482 (2012).
30. Lonial S, Kaufman JL. The era of combination therapy in myeloma. J. Clin. Oncol. 30(20), 2434-2436 (2012).
31. Voorhees PM, Gasparetto C, Osman K et al. Vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib (B) in patients with relapsed/refractory multiple myeloma (R/R MM): final results of a Phase I study. ASH Annual Meeting Abstracts 118(21), 3985 (2011).
32. San-Miguel J, Richardson P, Sezer O et al. A Phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. J. Clin. Oncol. 29(Suppl.), Abstract 8075 (2011).
33. San-Miguel J, Sezer O, Guenther A et al. Phase Ib dose-escalation study of oral panobinostat and IV bortezomib in patients with relapsed or relapsed and refractory multiple myeloma: updated results. Hematologica 96(Suppl 1), 238 (2011).
34. Richardson PG, Alsina M, Weber DM et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). ASH Annual Meeting Abstracts 118(21), 814 (2011).
35. Baughn LB, Di Liberto M, Wu K et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66(15), 7661-7667 (2006).
36. Menu E, Garcia J, Huang X et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 68(14), 5519-5523 (2008).
37. Niesvizky R, Ely S, Jayabalan DS et al. A Phase I trial of PD 0332991, a novel, orally-bioavailable CDK4/6-specific inhibitor administered in combination with bortezomib and dexamethasone to patients with relapsed and refractory multiple myeloma. ASH Annual Meeting Abstracts 114(22), 1877 (2009).
38. San Miguel JF, Schlag R, Khuageva NK et al.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906-917 (2008).
39. Miguel JFS, Schlag R, Khuageva NK et al. Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the Phase 3 VISTA trial. ASH Annual Meeting Abstracts 118(21), 476 (2011).
40. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J. Clin. Oncol. 28(34), 5101-5109 (2010).
41. Kumar S, Rajkumar SV. Many facets of bortezomib resistance/ susceptibility. Blood 112(6), 2177-2178 (2008).
42. Kupperman E, Lee EC, Cao Y et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70(5), 1970-1980 (2010).
43. Richardson PG, Baz R, Wang L et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a Phase 1 dose-escalation study. ASH Annual Meeting Abstracts 118(21), 301 (2011).
44. Kumar S, Bensinger WI, Reeder CB et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a Phase 1 doseescalation study. ASH Annual Meeting Abstracts 118(21), 816 (2011).
45. Berdeja JG, Richardson PG, Lonial S et al. Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Annual Meeting Abstracts 118(21), 479 (2011).
46. Sanchez E, Li M, Steinberg JA et al. Oral dosing of the novel proteasome inhibitor CEP-18770 shows marked antimyeloma effects in SCID-Hu models of multiple myeloma. ASH Annual Meeting Abstracts 114(22), 1840 (2009).
47. Piva R, Ruggeri B, Williams M et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5), 2765-2775 (2008).
48. Sanchez E, Nichols CM, Lam AC et al. Efficacy and tolerability of CEP-18770 in combination with dexamethasone and lenalidomide using a SCID-Hu model of multiple myeloma (MM). ASH Annual Meeting Abstracts 118(21), 2946 (2011).
49. Chauhan D, Catley L, Li G et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8(5), 407-419 (2005).
50. Richardson P, Hofmeister C, Jakubowiak A et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/ refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 114(22), 431 (2009).
51. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115(4), 834-845 (2010).
52. Chauhan D, Singh AV, Aujay M et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116(23), 4906-4915 (2010).
53. Papadopoulos K, Mendelson D, Tolcher A et al. A Phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. J. Clin. Oncol. 29(Suppl.), Abstract 3075 (2011).
54. Zhou HJ, Aujay MA, Bennett MK et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 52(9), 3028-3038 (2009).
55. O'Connor OA, Stewart AK, Vallone M et al in patients with hematologic malignancies. Clin. Cancer Res. 15(22), 7085-7091 (2009).
56. Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. ASH Annual Meeting Abstracts 110(11), 411 (2007).
57. Jagannath S, Vij R, Stewart K et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J. Clin. Oncol. 27(15 Suppl.), Abstract 8504 (2009).
58. Vij R, Kaufman JL, Jakubowiak AJ et al Final results from the bortezomib-naive group of PX-171-004, a Phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. ASH Annual Meeting Abstracts 118(21), 813 (2011).
59. Wang M, Bensinger W, Martin T et al. Interim results from PX-171-006, a Phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). J. Clin. Oncol. 29(Suppl.) Abstract 8025 (2011).
60. Moreau P, Palumbo A, Stewart A et al. A randomized, multicenter, Phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). J. Clin. Oncol. 29(Suppl.), Abstract TPS225 (2011).
61. Jakubowiak AJ, Dytfeld D, Jagannath S et al. Final results of a frontline Phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). ASH Annual Meeting Abstracts 118(21), 631 (2011).
62. Sonneveld P, Hacker E, Zweegman S et al. Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). A trial of the european myeloma network EMN. ASH Annual Meeting Abstracts 118(21), 633 (2011).
63. Popat R, Goff L, Oaekervee HE, Cavenagh JD, Joel SP. Changes in Mcl-1 and Bim expression with bortezomib and melphalan therapy for multiple myeloma. ASH Annual Meeting Abstracts 106(11), 2481 (2005).
64. Facon T, Mary JY, Hulin C et al.; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370(9594), 1209-1218 (2007).
65. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J. Clin. Oncol. 27(22), 3664-3670 (2009).
66. Wijermans P, Schaafsma M, van Norden Y et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the dutch cooperative group HOVON 49 Study. ASH Annual Meeting Abstracts 112(11), 649 (2008).
67. Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112(8), 3107-3114 (2008).
68. Beksac M, Haznedar R, Firatli-Tuglular T et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur. J. Haematol. 86(1), 16-22 (2011).
69. Fayers PM, Palumbo A, Hulin C et al.; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118(5), 1239-1247 (2011).
70. Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 99(12), 4525-4530 (2002).
71. Richardson PG, Jagannath S, Jakubowiak AJ et al. Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple myeloma (MM): updated efficacy and safety data after >2 years of follow-up. ASH Annual Meeting Abstracts 116(21), 3049 (2010).
72. Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5), 679-686 (2010).
73. Kumar S, Flinn IW, Richardson PG et al. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multicenter, randomized, Phase 2 EVOLUTION study. ASH Annual Meeting Abstracts 116(21), 621 (2010).
74. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev. Anticancer Ther. 6(8), 1165-1173 (2006).
75. Chang DH, Liu N, Klimek V et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 108(2), 618-621 (2006).
76. Tai YT, Li XF, Catley L et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 65(24), 11712-11720 (2005).
77. Lonial S, Jakubowiak AJ, Jagannath S et al. A Phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 118(21), 303 (2011).
78. Richardson PG, Siegel DS, Vij R et al. Randomized, open label Phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): Phase 2 results. ASH Annual Meeting Abstracts 118(21), 634 (2011).
79. Leleu X, Attal M, Arnulf B et al. High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. ASH Annual Meeting Abstracts 118(21), 812 (2011).
80. Palumbo A, Larocca A, Carella AM et al. A Phase I/II study of pomalidomidecyclophosphamide-prednisone (pcp) in patients with multiple myeloma relapsed/ refractory to lenalidomide. ASH Annual Meeting Abstracts 118(21), 632 (2011).
81. Mark TM, Rodriguez M, Shah M et al. ClaPD (clarithromycin/[Biaxin®], pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 118(21), 635 (2011).
82. Berenson JR, Yellin O, Bessudo A et al. Bendamustine combined with bortezomib has efficacy in patients with relapsed or refractory multiple myeloma: A Phase 1/2 study. ASH Annual Meeting Abstracts 118(21), 1857 (2011).
83. Lentzsch S, O'Sullivan A, Kennedy R et al in patients with refractory or relapsed multiple myeloma is safe and highly effective: results of Phase I/II open-label, dose escalation study. ASH Annual Meeting Abstracts 118(21), 304 (2011).
84. Ludwig H, Kasparu H, Linkesch W et al. Bortezomib-bendamustine- dexamethasone in patients with relapsed/refractory multiple myeloma (MM) shows marked efficacy and is well tolerated, but assessment of PNP symptoms shows significant discrepancies between patients and physicians. ASH Annual Meeting Abstracts 118(21), 2928 (2011).
85. Harousseau J-L. Maintenance therapy in multiple myeloma. Hematol. Rev. 1(2), e12 (2009).
86. Sahebi F, Frankel PH, Farol L et al. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Biol. Blood Marrow Transplant. 18(3), 486-492 (2012).
87. Kaufman JL, Nooka AK, Muppidi S et al. Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM). J. Clin. Oncol. 30(Suppl.), Abstract 8100 (2012).
88. Jagannath S, Barlogie B, Berenson J et al. A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 127(2), 165-172 (2004).
89. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 92(8), 1149-1150 (2007).
90. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999).
91. Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. 12(7), 991-995 (2001).
92. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regimen for previously treated patients with multiple myeloma. Hematol. J. 5, 112-117 (2004).
93. Kim YK, Sohn SK, Lee JH et al.; Korean Multiple Myeloma Working Party (KMMWP). Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: A Phase II study. Ann. Hematol. 89(5), 475-482 (2010).
94. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9), 3063-3067 (2002).
95. Weber DM, Chen C, Niesvizky R et al.; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007).
96. Dimopoulos M, Spencer A, Attal M et al.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007).
97. Richter JR, Bilotti E, McBride L et al. Salvage therapy with vorinostat, lenalidomide, and dexamethasone (ZRD) in lenalidomide/dexamethasone relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 118(21), 3986 (2011).
98. Richardson PG, Xie W, Mitsiades C et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 27(21), 3518-3525 (2009).
99. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III trial. J. Clin. Oncol. 28(30), 4621-4629 (2010).
100. Reeder C, Stewart A, Hentz J et al. Efficacy of induction with CyBorD in newly diagnosed multiple myeloma. J. Clin. Oncol. 26(Suppl.) Abstract 8517 (2008).
101. Rajkumar SV, Rosiñol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26(13), 2171-2177 (2008).
102. Lokhorst HM, Schmidt-Wolf I, Sonneveld P et al.; Dutch-Belgian HOVON; German GMMG. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93(1), 124-127 (2008).
103. Sonneveld P, Schmidt-Wolf I, van der Holt B et al. HOVON-65/GMMG-HD4 randomized Phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 116(21), 40 (2010).
104. Morgan GJ, Davies FE, Owen RG et al. Thalidomide combinations improve response rates; results from the MRC IX study. ASH Annual Meeting Abstracts 110(11), 3593 (2007).
105. Cavo M, Tacchetti P, Patriarca F et al. GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised Phase 3 study. Lancet 376(9758), 2075-2085 (2010).
106. Moreau P, Avet-Loiseau H, Facon T et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118(22), 5752-5758 (2011).
107. Rajkumar SV, Jacobus S, Callander NS et al.; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol. 11(1), 29-37 (2010).
108. Kumar S, Hayman S, Buadi F et al. Phase II trial of lenalidomide (RevlimidTM) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. ASH Annual Meeting Abstracts 112(11), 91 (2008).
109. Jakubowiak AJ, Griffith KA, Reece DE et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: A Phase 1/2 Multiple Myeloma Research Consortium trial. Blood 118(3), 535-543 (2011).
110. Kaufman JL, Shah JJ, Laubach JP et al. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): initial results of a Phase 1 study. ASH Annual Meeting Abstracts 116(21), 3034 (2010).